Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy

Next Previous
X
Search
Trial Profile

An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelecopan (Primary)
  • Indications IgA nephropathy; Membranoproliferative glomerulonephritis; Membranous glomerulonephritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RENEW
  • Sponsors BioCryst Pharmaceuticals

    • Most Recent Events

    • 15 Dec 2022 According to a BioCryst Pharmaceuticals media release, based on new competitive data recently presented at the American Society of Hematology (ASH) annual meeting, the company no longer believes that BCX9930 would be commercially competitive, and is discontinuing the development of BCX9930. This decision allows the company to fully focus its complement inhibitor development efforts on BCX10013
    • 15 Dec 2022 Status changed from recruiting to discontinued as per BioCryst Pharmaceuticals media release
    • 18 Nov 2022 Time frame for primary endpoint changed from week 24 to Week 12, 24, 36, 52. For first 2 weeks, dose changed to 200 mg twice daily and then 400 mg twice daily.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top